Literature DB >> 12172572

Markov model-based estimation of individual survival probability for medullary thyroid cancer patients.

Olga Esik1, Gábor Tusnády, Lajos Trón, András Boér, Zoltán Szentirmay, István Szabolcs, Károly Rácz, Erzsébet Lengyel, Judit Székely, Miklós Kásler.   

Abstract

UNLABELLED: The relatively benign, but occasionally rapidly fatal clinical course of medullary thyroid cancer (MTC) has raised the need for individual survival probability estimation. A retrospective study on 91 MTC clinical case histories with a mean follow-up of 6 years indicated prevalences of local, regional and distant residual tumor on primary care completion of 23%, 54% and 54%, respectively. Local, regional and distant relapses during follow-up occurred in 8%, 23% and 26% of the patients, with a cause-specific death in 26% of the cases. Prognostic factors statistically significantly influencing the cause-specific survival were selected by uni- and multivariate analysis. A Markov method-based model was developed for the estimation of individual time-dependent local, regional and distant relapse-free and cause-specific survival probability functions, with parameters numerically determined via a maximum likelihood procedure. These parameters include relative risk factors related to prognosticators, a residual or recurrent local/regional/distant tumor, and combinations of these entities. In multivariate studies, the patient s age and gender, the genetic basis of the dis-ease, lymph node involvement, the existence of a general symptom (diarrhoea) at presentation, and the dosage of external irradiation proved to be prognosticators. The cause-specific survival function of the study population indicated mean 5, 10 and 15-year survival probabilities of 69%, 62% and 58%.
CONCLUSION: Survival probabilities can be predicted for extrastudy cases provided that the same laws and principles govern the clinical course of these cases and those comprising the study. For individual survival probability estimation, a Pascal program (MEDUPRED) was written and is available on the home page of the National Institute of Oncology, Budapest (www.oncol.hu).

Entities:  

Mesh:

Year:  2002        PMID: 12172572     DOI: 10.1007/bf03033717

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  33 in total

1.  Management of medullary carcinoma of the thyroid.

Authors:  W J Simpson; J A Palmer; I B Rosen; R A Mustard
Journal:  Am J Surg       Date:  1982-10       Impact factor: 2.565

2.  Clinicopathologic and flow cytometric DNA study of medullary thyroid carcinoma.

Authors:  A K el-Naggar; N G Ordonez; D McLemore; P Schultz; R C Hickey; N Samaan
Journal:  Surgery       Date:  1990-12       Impact factor: 3.982

3.  Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary.

Authors:  I Klein; O Esik; V Homolya; F Szeri; A Váradi
Journal:  J Endocrinol       Date:  2001-09       Impact factor: 4.286

4.  Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

Authors:  F D Gilliland; W C Hunt; D M Morris; C R Key
Journal:  Cancer       Date:  1997-02-01       Impact factor: 6.860

5.  Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients.

Authors:  L Scopsi; G Sampietro; P Boracchi; R Del Bo; M Gullo; M Placucci; S Pilotti
Journal:  Cancer       Date:  1996-11-15       Impact factor: 6.860

6.  Nuclear DNA content and survival in medullary thyroid carcinoma. Swedish Medullary Thyroid Cancer Study Group.

Authors:  E T Ekman; U Bergholm; M Bäckdahl; H O Adami; R Bergström; L Grimelius; G Auer
Journal:  Cancer       Date:  1990-02-01       Impact factor: 6.860

7.  Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma.

Authors:  H Dralle; I Damm; G F Scheumann; J Kotzerke; E Kupsch; H Geerlings; R Pichlmayr
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

Review 8.  Thyroid cancer nodal metastases: biologic significance and therapeutic considerations.

Authors:  S K Grebe; I D Hay
Journal:  Surg Oncol Clin N Am       Date:  1996-01       Impact factor: 3.495

9.  Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients.

Authors:  M F Saad; N G Ordonez; R K Rashid; J J Guido; C S Hill; R C Hickey; N A Samaan
Journal:  Medicine (Baltimore)       Date:  1984-11       Impact factor: 1.889

10.  Medullary thyroid carcinoma: prognostic factors and treatment.

Authors:  P Rougier; C Parmentier; A Laplanche; M Lefevre; J P Travagli; B Caillou; M Schlumberger; J Lacour; M Tubiana
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-02       Impact factor: 7.038

View more
  3 in total

1.  Adjuvant external beam radiation for medullary thyroid carcinoma.

Authors:  Steve R Martinez; Shannon H Beal; Allen Chen; Steven L Chen; Philip D Schneider
Journal:  J Surg Oncol       Date:  2010-08-01       Impact factor: 3.454

2.  Treating medullary thyroid carcinoma in a tertiary center. Current trends and review of the literature.

Authors:  E Prokopakis; M Doulaptsi; A Kaprana; S Velegrakis; Y Vlastos; G Velegrakis
Journal:  Hippokratia       Date:  2014-04       Impact factor: 0.471

3.  Prognosis of radiotherapy in medullary thyroid carcinoma patients without distant metastasis.

Authors:  Shaojun Huang; Jiana Zhong; Zhen Zhang; Rongping Chen; Jitong Li; Jia Sun; Hong Chen
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.